Complement Therapeutics Announces FDA Fast Track Designation for CTx001 for the Treatment of Geographic Atrophy Secondary to AMD

Complement Therapeutics GmbH (CTx), a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug ...
Healio

FDA fast tracks CTx001 for geographic atrophy

The FDA granted fast track designation for CTx001, an investigational gene therapy candidate for geographic atrophy secondary ...
Pharmabiz

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy

US FDA grants fast track designation to Complement Therapeutics’ gene therapy candidate CTx001 to treat geographic atrophy: Munich Saturday, January 10, 2026, 17:00 Hrs [IST] Co ...
Yahoo Finance

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and preliminary efficacy of CTx001 as a potential one-time treatment for GA Opti-GAIN builds on insights from i-GAIN, a ...
Seeking Alpha

Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results, ...
Business Wire

Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement Therapeutics

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular ...
Newswire

Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD

CTx001 is an investigational AAV-based gene therapy designed to modulate multiple pathways of the complement system Opti-GAIN is a first-in-human trial to evaluate the safety, tolerability, and ...